Abstracts tagged "dendritic cells and systemic sclerosis"

Abstract Number: 1123 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Bronchoalveolar Lavage Correlate with Pulmonary Artery Diameter and Infiltrate Perivascular Areas in the Lungs from Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Isela Valera¹, Anagha Divekar², Dinesh Khanna³, Fereidoun Abtin⁴, Rajan Saggar⁴ and Ram R. Singh⁴, ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, ²Biolegend, Sa Diego, CA, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁴UCLA, Los Angeles, CA
Background/Purpose: In patients with systemic sclerosis (SSc), plasmacytoid dendritic cells (pDCs) increase in the bronchoalveolar lavage (BAL) and lung tissues (Kafaja S, et al, JCI…
Abstract Number: 950 • 2017 ACR/ARHP Annual Meeting
Identification of Naturally Processed Immunodominant Topoisomerase I Epitopes in Patients with Systemic Sclerosis
Eleni Tiniakou¹, Andrea Fava², Tara Guhr³, Francesco Boin⁴ and Erika Darrah⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of North Carolina, Chapel Hill, NC, ⁴Rheumatology, University California, San Francisco, San Francisco, CA, ⁵Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Identification of immunodominant T cell epitopes of autoantigens is crucial to understanding the pathogenesis of autoimmune diseases and developing disease-specific diagnostic and therapeutic tools.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].